Physician profile
Laura Baker
NPI 1326451063
$2,754.62
in general payments reported to CMS, 2019-2025
30 companies · $42.67 in 2025
The $42.67 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $248 · 2021: $208 · 2022: $630 · 2023: $230 · 2024: $585 · 2025: $42.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $566.02 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $345.40 | 2019-2024 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $243.34 | 2022-2024 | |
| Lilly USA, LLC | $211.89 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $192.56 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.53 | 2019-2024 | Jardiance |
| Inspire Medical Systems, INC. | $175.12 | 2024 | Inspire |
| Abbott Laboratories | $144.55 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $92.58 | 2019-2022 | |
| Nevro Corp. | $65.19 | 2021 | |
| Amarin Pharma, INC. | $57.02 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.35 | 2019-2020 | |
| Hydrocision, INC. | $41.45 | 2022 | |
| Dexcom, INC. | $38.34 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $30.96 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.72 | 2020-2022 | |
| Allergan, INC. | $29.29 | 2019-2020 | |
| Amgen INC. | $27.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.80 | 2019 | |
| Biogen, INC. | $22.56 | 2021 | |
| Hikma Pharmaceuticals USA | $21.99 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.34 | 2022 | |
| Astellas Pharma US INC | $19.05 | 2023 | Veozah |
| Sunovion Pharmaceuticals INC. | $18.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.07 | 2019 | |
| Genentech USA, INC. | $15.77 | 2022 | |
| Medtronic, INC. | $15.27 | 2022 | |
| Abbvie INC. | $15.11 | 2022 | |
| Sanofi Pasteur INC. | $14.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.